Table 4.

Estimates used to calculate effect of thrombophilia testing in individuals with a family history of VTE

Thrombophilia defect in the family	RR for first VTE, positive vs negative (95% CI)	Treatment effect for VTE occurrence, RR (95% CI)∗	Treatment effect major bleeding, RR (95% CI)∗
FVL (FVL)	2.71 (2.06-3.56)	0.54 (0.32-0.91)	2.09 (1.33-3.27)
Prothrombin (PT) mutation	2.35 (1.46-3.78)
Antithrombin (AT) deficiency	12.17 (5.45-27.17)
Protein C (PC) deficiency	7.47 (2.81-19.81)
Protein S (PS) deficiency	5.98 (2.45-14.57)

^∗Estimates taken from ASH Medical Prophylaxis guideline-medical outpatients with minor provoking risk factors for VTE.